Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES-Reference-Cited by-同舟云学术

Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES

Published:2016-03-25 Issue:1 Volume:64 Page:47-57
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Simon Tracey G.¹²,Bonilla Hector³,Yan Peng⁴⁵,Chung Raymond T.¹²,Butt Adeel A.⁴⁵⁶

Affiliation:

1. Liver Center, Gastrointestinal Division, Department of Medicine; Massachusetts General Hospital; Boston MA

2. Harvard Medical School; Boston MA

3. Diablo Infectious Diseases; Castro Valley CA

4. Weill Cornell Medical College, Doha; Qatar and New York NY

5. University of Pittsburgh School of Medicine; Pittsburgh PA

6. Hamad Healthcare Quality Institute and Hamad Medical Corporation; Doha Qatar

Funder

National Institutes of Health

Publisher

Wiley

Subject

Hepatology

Reference52 articles.

1. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002;Armstrong;Ann Intern Med,2006

2. Natural history of hepatitis C;Thomas;Clin Liver Dis,2005

3. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis;Meer;JAMA,2012

4. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;J Am Coll Cardiol,2014

5. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients;Sun;Clin Infect Dis,2009

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease;Gut;2024-08-01

2. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy;Clinical and Molecular Hepatology;2024-07-01

3. Statins as anti‐tumor agents: A paradigm for repurposed drugs;Cancer Reports;2024-05

4. The Upregulation of Leucine-Rich Repeat Containing 1 Expression Activates Hepatic Stellate Cells and Promotes Liver Fibrosis by Stabilizing Phosphorylated Smad2/3;International Journal of Molecular Sciences;2024-02-27

5. A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin;Microorganisms;2024-02-13